

TECH CENTER 1600/2900

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
on Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PETITION FOR EXTENSION OF TIME UNDER 37 CFR 1.136(a)

Docket Number (Optional) BAYER-15A

| CADEND   |   |                           | <u></u>                      |
|--|---|---------------------------|------------------------------|
|  | In re Application of Bernd RIEDL et al.                                       |                           |                              |
|  | Application Number 09/889,227 Filed January 8, 2002                           |                           |                              |
|  | For $\omega$ -CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |                           |                              |
|  | Group Art Unit<br>1625  | Examiner<br>Rita J. DESAI |                              |
| This is a request under the provisions of 37 CFR 1.136(a) to extend the period for filing a  |   |                           |                              |
| response in the above identified application.  |   |                           |                              |
| The requested extension and appropriate non-small-entity fee are as follows (check time period desired):   |   |                           |                              |
|  |   |                           | \$ <u>110.00</u>             |
| ☐ Two months (37 CFR 1.17(a)(2))   |   |                           | \$                           |
| Three months (37 CFR 1.17(a)(3))   |   |                           | \$                           |
| Four months (37 CFR 1.17(a)(4))  |   |                           | \$                           |
| ☐ Five months (37 CF   | ns (37 CFR 1.17(a)(5))  |                           | \$                           |
| <ul> <li>Applicant claims small entity status. See 37 CFR 1.27. Therefore, the fee amount shown above is reduced by one-half, and the resulting fee is: \$</li> <li>A check in the amount of the fee is enclosed.</li> <li>Payment by credit card. Form PTO-2038 is attached.</li> <li>The Commissioner has already been authorized to charge fees in this application to a Deposit Account.</li> <li>The Commissioner is hereby authorized to charge any fees which may be required, or credit any overpayment, to Deposit Account Number 13-3402.</li> <li>I have enclosed a duplicate copy of this sheet.</li> <li>I am the ☐ applicant/inventor.</li> <li>☐ assignee of record of the entire interest. See 37 CFR 3.71</li> <li>Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).</li> <li>☐ attorney or agent of record.</li> <li>☐ attorney or agent under 37 CFR 1.34(a).</li> <li>Registration number if acting under 37 CFR 1.34(a).</li> </ul> |   |                           |                              |
| WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.   |   |                           |                              |
| December 19, 2002  |   | 00                        | 4/h                          |
| Date   |   |                           | Signature                    |
|  |   |                           | J. Traverso, Reg. No. 30,595 |
|  |   | т                         | yped or printed name         |
| OTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple orms if more than one signature is required, see below*.   |   |                           |                              |
| *Total of forms are submitted.   |   |                           |                              |

Burden Hour Statement: This form is estimated to take 0.1 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

K:\Bayer\15A\EOT for RR.doc